H5N1 has been circulating in birds for years. The reason it is getting more attention now is specific and worth understanding clearly.

The virus crossed into cattle in the US in 2024 — an unexpected host jump that expanded the pool of potential human exposure significantly. Dairy farm workers have tested positive in multiple states. Most cases involved mild illness: eye irritation, respiratory symptoms, rapid recovery. No sustained human-to-human transmission has been documented. That last sentence is the most important one in any bird flu discussion, and it remains true as of now.

2025 was confirmed as the hottest year in recorded human history, continuing a streak that has now run for over a decade. The science is not the contested part anymore. What deserves more attention is the gap between what is being done and what the models say is necessary.

Global renewable energy deployment is genuinely accelerating. Solar installation in particular has beaten nearly every projection made ten years ago — costs have fallen faster and adoption has spread wider than analysts expected. This is good news and it is real. The problem is that it is happening alongside continued fossil fuel use rather than replacing it at the rate required to hit agreed temperature targets.

Ozempic and Wegovy get talked about as weight loss drugs. That framing is increasingly inadequate for what GLP-1 receptor agonists appear to be doing.

The weight loss results are real and significant — patients losing 15 to 20% of body weight in clinical trials far exceeds what any previous pharmaceutical intervention achieved. But the downstream effects are where the story gets more interesting. Large-scale trials have shown meaningful reductions in cardiovascular events — heart attacks and strokes — in patients taking semaglutide, independent of weight loss effects. Separate research is showing promising signals in addiction behavior: patients reporting reduced cravings not just for food but for alcohol, nicotine, and other substances.